Female cancer types
Pro Research Analysisby 
Searched over 200M research papers
Major Female Cancer Types: Breast, Gynecological, and Hormone-Related Cancers
Female cancer types primarily include breast cancer and gynecological cancers such as cervical, ovarian, uterine (endometrial), vaginal, and vulvar cancers. These cancers account for a significant proportion of cancer cases and deaths among women globally, with breast, cervical, ovarian, and uterine cancers alone making up nearly 40% of all cancers in women 12. Breast cancer is the most common, followed by cervical, ovarian, and uterine cancers. Other less common but important types include vaginal and vulvar cancers, as well as gestational trophoblastic neoplasia (GTN) .
Epidemiology and Global Burden of Female Cancers
The global burden of female-specific cancers has increased over recent decades, with breast cancer leading in incidence and mortality. In 2021, there were over 2 million new breast cancer cases worldwide, compared to 670,000 cervical, 300,000 ovarian, and 470,000 uterine cancer cases . The burden of these cancers varies by region and is influenced by socioeconomic factors. Higher socioeconomic development is associated with increased rates of breast, ovarian, and uterine cancers, while cervical cancer is more common in lower socioeconomic regions 18. In China, breast cancer alone accounted for over 350,000 new cases and 75,000 deaths in 2022, with higher rates in urban areas and among women over 55 years old .
Risk Factors and Regional Differences
Risk factors for female cancers include high body-mass index (BMI), dietary habits, high fasting plasma glucose, alcohol and tobacco use, low physical activity, and unsafe sex (especially for cervical cancer) 18. High BMI is a leading risk factor for uterine and ovarian cancers, while dietary risks and lifestyle factors are significant for breast cancer. Cervical cancer is strongly linked to unsafe sex and human papillomavirus (HPV) infection 18. Regional differences in cancer burden are shaped by these risk factors, as well as by cultural and socioeconomic contexts .
Molecular and Genetic Insights in Female Cancers
Recent research highlights the role of molecular factors such as long non-coding RNAs (lncRNAs) and androgen receptors in the development and progression of female cancers. LncRNAs like HOTAIR, NEAT1, H19, MALAT1, and MEG3 can act as either tumor suppressors or promoters, influencing cancer cell invasion, proliferation, metastasis, and drug resistance . Androgen receptors are also implicated in ovarian, endometrial, and cervical cancers, affecting tumor growth and response to therapy . The TET2 gene has been identified as a potential marker for prognosis in breast, cervical, ovarian, and uterine cancers, with higher expression linked to better outcomes .
Secondary Cancer Risks and Survivorship
Women diagnosed with hormone-related cancers (breast, endometrial, cervical, ovarian) have a higher risk of developing subsequent primary lung cancer compared to the general population, and this risk increases with longer survival . Survivors of breast cancer, in particular, face increased risks of suicide, especially among younger, unmarried, and certain molecular subtypes (HER-2, triple-negative) .
Prevention, Diagnosis, and Treatment Advances
Prevention strategies include HPV vaccination for cervical cancer and lifestyle modifications to reduce risk factors such as obesity and tobacco use 15. Peptide vaccines are being developed for both therapeutic and preventive purposes, targeting tumor-associated antigens and viral causes of female-specific cancers . Molecular subtyping, especially in breast cancer, guides treatment decisions and helps predict outcomes, with hormone receptor-positive and HER2-positive subtypes being most common .
Conclusion
Female cancer types encompass a range of malignancies, with breast, cervical, ovarian, and uterine cancers being the most prevalent. The burden of these cancers is rising globally, influenced by socioeconomic, lifestyle, and molecular factors. Advances in molecular biology, prevention, and targeted therapies offer hope for improved diagnosis, treatment, and outcomes for women affected by these cancers 1245+3 MORE.
Sources and full results
Most relevant research papers on this topic